- Kezar Life Sciences Inc at Morgan Stanley Global Healthcare Conference TranscriptSep 12, 2023
- Kezar Life Sciences Inc at Wells Fargo Healthcare Conference TranscriptSep 07, 2023
- Kezar Life Sciences Inc at Jefferies Healthcare Conference TranscriptJun 08, 2023
- Kezar Life Sciences Inc R&D Day TranscriptMar 15, 2023
- Alpine Immune Sciences Inc and Kezar Life Sciences Inc at Cowen Health Care Conference- Panel TranscriptMar 07, 2023
- Kezar Life Sciences Inc at JPMorgan Healthcare Conference TranscriptJan 11, 2023
- Kezar Life Sciences Inc at Evercore ISI HealthCONx Conference (Virtual) TranscriptNov 30, 2022
- Kezar Life Sciences Inc at Morgan Stanley Global Healthcare Conference TranscriptSep 14, 2022
- Kezar Life Sciences Inc Topline Results from the MISSION Phase 2 Clinical Trial Evaluating Zetomipzomib - Corporate Call TranscriptJun 27, 2022
- Kezar Life Sciences Inc Annual Shareholders Meeting TranscriptJun 25, 2021
- Kezar Life Sciences Inc At TMA's International Annual Patient Conference TranscriptSep 22, 2020
- Q2 2020 Kezar Life Sciences Inc Earnings Call TranscriptAug 05, 2020$4.72 (+1.83%)Earnings
- Kezar Life Sciences Inc At MSU: Rare Disease Day Presentation TranscriptApr 15, 2020
- Kezar Life Sciences Inc At PRESIDIO Clinical Trial of KZR-616 TranscriptMar 05, 2020
Kezar Life Sciences Inc at Jefferies Healthcare Conference Transcript
My name is Maury Raycroft, and I'm one of the biotech analysts at Jefferies. And I'd like to welcome the Kezar team with me today, and we're going to do a fireside chat discussion. Maybe to start off if you want to provide a one-minute intro to Kezar.
Yeah, hi, everybody. Thanks for joining us today. My name is John Fowler. I'm Co-Founder and CEO of Kezar. Founded the company in 2015 and actually met Maury in 2018. We've been working together for five years now.
We're based in the San Francisco Bay area, went public in 2018, and we actually have two drugs in the clinic at this time. Our lead asset is a small molecule called zetomipzomib -- we'll refer to it as zeto today -- is a selective immunoproteasome inhibitor. We have seen some amazing results to date, treating patients with both lupus and lupus nephritis, and we're currently enrolling a Phase 2b in lupus nephritis and also a Phase 2 in autoimmune hepatitis.
Our other clinical asset is a
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
![](https://static.gurufocus.com/material/money-back-guarantee.png)
![](https://static.gurufocus.com/trust_rating.png)
![](https://static.gurufocus.com/trust.png)